These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
594 related articles for article (PubMed ID: 17875725)
1. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725 [TBL] [Abstract][Full Text] [Related]
2. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane. Hasinoff BB; Patel D; Wu X Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377 [TBL] [Abstract][Full Text] [Related]
4. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834 [TBL] [Abstract][Full Text] [Related]
5. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy. Ma Y; North BJ; Shu J Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738 [TBL] [Abstract][Full Text] [Related]
6. Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia. Azarova AM; Lin RK; Tsai YC; Liu LF; Lin CP; Lyu YL Biochem Biophys Res Commun; 2010 Aug; 399(1):66-71. PubMed ID: 20638367 [TBL] [Abstract][Full Text] [Related]
7. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition. Hasinoff BB; Patel D; Wu X Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440 [TBL] [Abstract][Full Text] [Related]
8. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189 [TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib. Hasinoff BB; Patel D; Wu X Cardiovasc Toxicol; 2017 Jul; 17(3):237-250. PubMed ID: 27388042 [TBL] [Abstract][Full Text] [Related]
11. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity. Spagnuolo RD; Recalcati S; Tacchini L; Cairo G Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037 [TBL] [Abstract][Full Text] [Related]
12. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Vejpongsa P; Yeh ET Clin Pharmacol Ther; 2014 Jan; 95(1):45-52. PubMed ID: 24091715 [TBL] [Abstract][Full Text] [Related]
13. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage. Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791 [TBL] [Abstract][Full Text] [Related]
14. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135 [TBL] [Abstract][Full Text] [Related]
15. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway. Xiao H; Mao Y; Desai SD; Zhou N; Ting CY; Hwang J; Liu LF Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3239-44. PubMed ID: 12629207 [TBL] [Abstract][Full Text] [Related]
16. A protease pathway for the repair of topoisomerase II-DNA covalent complexes. Zhang A; Lyu YL; Lin CP; Zhou N; Azarova AM; Wood LM; Liu LF J Biol Chem; 2006 Nov; 281(47):35997-6003. PubMed ID: 16973621 [TBL] [Abstract][Full Text] [Related]
17. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis. Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547 [TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis. Lin RK; Ho CW; Liu LF; Lyu YL J Biol Chem; 2013 Mar; 288(10):7182-92. PubMed ID: 23344961 [TBL] [Abstract][Full Text] [Related]
19. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity. Bavlovič Piskáčková H; Jansová H; Kubeš J; Karabanovich G; Váňová N; Kollárová-Brázdová P; Melnikova I; Jirkovská A; Lenčová-Popelová O; Chládek J; Roh J; Šimůnek T; Štěrba M; Štěrbová-Kovaříková P Sci Rep; 2021 Feb; 11(1):4456. PubMed ID: 33627707 [TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]